New Psychosis Findings Has Been Reported by Investigators at Kore University of Enna (Impact of Selected Second and Third Generation Antipsychotics On Cognitive Dysfunction In Schizophrenia-spectrum Disorders. Systematic Review and Network...).

This article focuses on a systematic review and network meta-analysis conducted by researchers at Kore University of Enna, Italy, examining the cognitive effects of selected second- and third-generation antipsychotics (TGAs) in schizophrenia-spectrum disorders. The study analyzed randomized controlled trials involving drugs such as brexpiprazole, cariprazine, lumateperone, lurasidone, and xanomeline-trospium, alongside second-generation antipsychotics like aripiprazole and olanzapine. Findings indicated that lurasidone and xanomeline improved global cognitive performance, while quetiapine and cariprazine showed benefits in attention, with cognitive improvements independent of psychotic symptom changes or patient age. The research suggests that certain antipsychotics, including M1/M4 receptor agonists like xanomeline, may offer promising treatments for cognitive dysfunction in schizophrenia, highlighting the need for personalized pharmacological approaches based on cognitive profiles. [Extracted from the article]